
Ulla Knorr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2980167/publications.pdf Version: 2024-02-01



HULL KNORD

#	Article	IF	CITATIONS
1	Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. Journal of Affective Disorders, 2022, 297, 623-633.	4.1	13
2	Norms for the Screen for Cognitive Impairment in Psychiatry and cognitive trajectories in bipolar disorder. Journal of Affective Disorders, 2021, 281, 33-40.	4.1	18
3	The impact of the trajectory of bipolar disorder on global cognitive function: A one-year clinical prospective case-control study. Journal of Affective Disorders, 2021, 278, 189-198.	4.1	10
4	Associations between oxidative stress and perceived stress in patients with bipolar disorder and healthy control individuals. Nordic Journal of Psychiatry, 2021, 75, 532-537.	1.3	3
5	Dynamic LED-light versus static LED-light for depressed inpatients: study protocol for a randomised clinical study. BMJ Open, 2020, 10, e032233.	1.9	1
6	Etomidate enabled electroconvulsive therapy without suppressing adrenocortical function in a case with difficulties in inducing seizures by conventional methods. Psychiatry and Clinical Neurosciences, 2020, 74, 624-626.	1.8	0
7	The impact of a new affective episode on psychosocial functioning, quality of life and perceived stress in newly diagnosed patients with bipolar disorder: A prospective one-year case-control study. Journal of Affective Disorders, 2020, 277, 486-494.	4.1	3
8	A randomized placeboâ€controlled trial examining the effects of escitalopram on neuroticism and state anxiety in a nonclinical sample. Human Psychopharmacology, 2019, 34, e2711.	1.5	1
9	Low level of evidence for reduced homovanillic acid (HVA) in the cerebrospinal fluid of patients with depression compared to healthy non-psychiatric control individuals. Journal of Affective Disorders, 2019, 257, 585-588.	4.1	0
10	Cerebrospinal fluid oxidative stress metabolites in patients with bipolar disorder and healthy controls: a longitudinal case-control study. Translational Psychiatry, 2019, 9, 325.	4.8	31
11	The effect of selective serotonin reuptake inhibitors in healthy subjects revisited: A systematic review of the literature Experimental and Clinical Psychopharmacology, 2019, 27, 413-432.	1.8	18
12	Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review. European Neuropsychopharmacology, 2018, 28, 783-794.	0.7	18
13	Poor evidence for putative abnormalities in cerebrospinal fluid neurotransmitters in patients with depression versus healthy non-psychiatric individuals: A systematic review and meta-analyses of 23 studies. Journal of Affective Disorders, 2018, 240, 6-16.	4.1	21
14	Influences of patient informed cognitive complaints on activities of daily living in patients with bipolar disorder. An exploratory cross-sectional study. Psychiatry Research, 2017, 249, 268-274.	3.3	19
15	Increased blood BDNF in healthy individuals with a family history of depression. Psychiatry Research, 2017, 256, 176-179.	3.3	16
16	The relationship between self-reported childhood adversities, adulthood psychopathology and psychological stress markers in patients with schizophrenia. Comprehensive Psychiatry, 2017, 72, 48-55.	3.1	16
17	No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial. Acta Neuropsychiatrica, 2016, 28, 101-109.	2.1	6
18	Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. Journal of Affective Disorders, 2016, 205, 378-386.	4.1	110

Ulla Knorr

#	Article	IF	CITATIONS
19	Effect of escitalopram versus placebo on GRα messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression – a secondary outcome analysis from the randomized AGENDA trial. Nordic Journal of Psychiatry, 2016, 70, 297-302.	1.3	4
20	Impaired down-regulation of negative emotion in self-referent social situations in bipolar disorder: A pilot study of a novel experimental paradigm. Psychiatry Research, 2016, 238, 318-325.	3.3	23
21	Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a casea€"control study. BMC Psychiatry, 2015, 15, 67.	2.6	9
22	Electronic monitoring of psychomotor activity as a supplementary objective measure of depression severity. Nordic Journal of Psychiatry, 2015, 69, 118-125.	1.3	16
23	Familial Risk for Major Depression is Associated with Lower Striatal 5-HT4 Receptor Binding. International Journal of Neuropsychopharmacology, 2015, 18, pyu034-pyu034.	2.1	35
24	Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools. Journal of Affective Disorders, 2015, 187, 10-19.	4.1	97
25	Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Research, 2013, 209, 417-423.	3.3	75
26	Cognitive deficits in the remitted state of unipolar depressive disorder Neuropsychology, 2012, 26, 642-651.	1.3	83
27	The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression—A randomised trial. Psychiatry Research, 2012, 200, 354-360.	3.3	19
28	Differences in psychomotor activity in patients suffering from unipolar and bipolar affective disorder in the remitted or mild/moderate depressive state. Journal of Affective Disorders, 2012, 141, 457-463.	4.1	71
29	Effect of Chronic Escitalopram versus Placebo on Personality Traits in Healthy First-Degree Relatives of Patients with Depression: A Randomized Trial. PLoS ONE, 2012, 7, e31980.	2.5	13
30	No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression. Journal of Neuroimmunology, 2012, 243, 69-72.	2.3	16
31	Escitalopram and Neuroendocrine Response in Healthy First-Degree Relatives to Depressed Patients – A Randomized Placebo-Controlled Trial. PLoS ONE, 2011, 6, e21224.	2.5	12
32	Volume of the adrenal and pituitary glands in depression. Psychoneuroendocrinology, 2011, 36, 19-27.	2.7	40
33	Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review. Journal of Affective Disorders, 2011, 134, 20-31.	4.1	335
34	A randomized trial of the effect of escitalopram versus placebo on cognitive function in healthy first-degree relatives of patients with depression. Therapeutic Advances in Psychopharmacology, 2011, 1, 133-144.	2.7	8
35	Salivary cortisol in depressed patients versus control persons: A systematic review and meta-analysis. Psychoneuroendocrinology, 2010, 35, 1275-1286.	2.7	247
36	The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review. Nordic Journal of Psychiatry, 2010, 64, 153-163.	1.3	23

Ulla Knorr

#	Article	IF	CITATIONS
37	The BDNF Val66Met polymorphism: Relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. Psychoneuroendocrinology, 2009, 34, 1380-1389.	2.7	46
38	Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. Trials, 2009, 10, 66.	1.6	13